Action:
Asciminib, branded as LuciAsc, is an allosteric inhibitor of the BCR-ABL protein. Unlike traditional tyrosine kinase inhibitors (TKIs) that bind to the ATP-binding site of the BCR-ABL protein, LuciAsc binds to a different site, known as the allosteric site. This binding prevents the BCR-ABL protein from activating, which is crucial in the progression of CML. By targeting this alternative binding site, LuciAsc overcomes resistance mechanisms associated with other TKIs, offering a new avenue for treatment.
Side Effects:
As with any medication, LuciAsc may cause side effects, including:
- Hematologic Effects: Decreased blood cell counts, such as anemia, thrombocytopenia (low platelet count), or neutropenia (low white blood cell count).
- Gastrointestinal Issues: Nausea, diarrhea, and abdominal pain.
- Fatigue: Patients may experience varying degrees of fatigue.
- Hepatic Effects: Liver enzyme elevations, which require monitoring.
- Headaches and Dizziness: Some patients may report these symptoms.
Regular monitoring and management strategies are essential to address these side effects effectively.
Reviews
There are no reviews yet.